Publications 1997-2005
2005
1 Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. D Konopnicki, A Mocroft, S De Wit, F Antunes, B Ledergerber, C Katlama, K Zilmer, S Vella, O Kirk, and JD Lundgren for the EuroSIDA Group.
AIDS. 2005 Apr 8;19(6):593-601 abstract
2 Risk of AIDS and death at given HIV-RNA and CD4 count levels, according to specific antiretroviral drugs in the regimen. Holkmann Olsen C, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren J, Phillips A.
AIDS. 2005 Feb 18; 19:319-330 abstract
3 Decline in oesophageal candidiasis and use of antimycotics in patients with HIV. A Mocroft, C Oancea, J van Lunzen, P Vanhems, D Banhegyi, A Chiesi, E Vinogradova, S Maayan, AN Phillips and J Lundgren.
Am J Gastroenterol. 2005 Jul;100(7):1446-54. abstract
4 Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. A Mocroft, AN. Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, JD Lundgren
AIDS Res Hum Retroviruses. Sep 2005, Vol. 21, No. 9: 743-752 abstract
5 Influence of Hepatitis C on HIV Disease Progression and Response to Antiretroviral Therapy. J Rockstroh, A Mocroft, V Soriano, C Tural, M Losso, A Horban, O Kirk, A Phillips, B Ledergerber, J Lundgren for the EuroSIDA study group.
J Infect Dis. 2005 Sep 15;192(6):992-1002 abstract
6 Is there evidence for an increase in the death-rate from liver-related disease in patients with HIV? A Mocroft, V Soriano, J Rockstroh, P Reiss, O Kirk, S de Wit, J Gatell, B Clotet, AN Phillips, JD Lundgren for the EuroSIDA study group.
AIDS. 2005 Dec 2; 19(18):2117-2125 abstract
7 Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? A Mocroft, J Rockstroh, V Soriano, B Ledergerber, O Kirk, E Vinogradova, P Reiss, C Katlama, AN Phillips, JD Lundgren for the EuroSIDA study group.
Antivir. Ther. 2005;10(7):779-90 abstract
8 Predictors of hypertension and changes of blood pressure in HIV-infected patients. R Thiebaut, WM El-Sadr, N Friis-Moller, M Rickenbach, P Reiss, AD Monforte, L Morfeldt, E Fontas, O Kirk, S De Wit, G Calvo, MG Law, F Dabis, CA Sabin, JD Lundgren; Data Collection of Adverse events of anti-HIV Drugs Study Group.
Antivir Ther. 2005;10(7):811-23 abstract
9 Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. E Girardi, CA Sabin, A d'Arminio Monforte, B Hogg, AN Phillips, MJ Gill, F Dabis, P Reiss, O Kirk, E Bernasconi, S Grabar, A Justice, S Staszewski, G Fatkenheuer, JA Sterne; Antiretroviral Therapy Cohort Collaboration.
Clin Infect Dis. 2005 Dec 15;41(12):1772-82. abstract
10 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. A Cozzi-Lepri, L Ruiz, C Loveday, AN Phillips, B Clotet, P Reiss, B Ledergerber, C Holkman Olsen, S Staszewski and JD Lundgren for the EuroSIDA Study Group.
Antivir. Ther. 2005;10(7):791-802 abstract
11 The ART Cohort Collaboration: AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? Writing committee: Sabin, CA, Hogg B, Dabis F, Gill MJ, Phillips AN, Reiss P, Fätkenheuer G, Grabar S, Lundgren J, Justice A, Ledergerber B, d'Arminio Monforte A, Staszewski A and Sterne JAC.
AIDS 2005 19: 1995-2000
12 Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. Margaret May, Kholoud Porter, Jonathan A. C. Sterne, Patrick Royston, Matthias Egger, ART-CC (The Antiretroviral Therapy Cohort Collaboration) and CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe).
Journal of Clinical Epidemiology 2005 58: 1033-1041
13 The ART Cohort Collaboration: The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Writing committee: D'Arminio MA, Sabin CA, Phillips A, Sterne JAC, May M, Justice AC, Dabis F, Grabar C, Ledergerber B, Gill J, Reiss P and Egger M. Archives of Internal Medicine 2005 165: 416-23
2004
1 Changing incidence of central nervous system diseases in the EuroSIDA cohort. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J; EuroSIDA Study Group.
Ann Neurol. 2004 Mar;55(3):320-8
abstract
2 Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P; D:A:D Study Group
J Infect Dis. 2004 Mar 15;189(6):1056-74
abstract
3 The Changing pattern of Kaposi´s sarcoma in patients with HIV - 1994-2003. The EuroSIDA Study. Mocroft A, Kirk O, Clumeck N, Gargalianos P, Trocha H, Chentsova N, Antunes F, Stellbrink H-J, Phillips AN, Lundgren JD for the EuroSIDA study group.
Cancer 2004; 100:2644-2654
abstract
4 Predictors of immunological failure after initial response to HAART in HIV-1 infected adults: a EuroSIDA study. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AE, Panos G, Mercey D, Machala L, Horban A, and Lundgren JD; EuroSIDA study group.
J Infect Dis. 2004 Jul 1;190(1):148-55
abstract
5 Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration.
Lancet. 2004 Jul 3;364(9428):51-62.
abstract
6 Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe. A EuroSIDA study, 1994-2000. Yust I, Fox Z, Burke M, Johnson AM, Tuner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O, for the EuroSIDA study.
Eur J Clin Microbiol Infect Dis. 2004 Jul;23(7):550-9
abstract
7 Baseline Resistance and Virologic Outcome in Patients with Virologic Failure who start a Regimen Containing Abacavir: EuroSIDA Study. Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjær J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA study group.
Antivir Ther. 2004 Oct;9(5):787-800
abstract
8 Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulcahy F, Fisher M, Machala L, Lundgren JD; EuroSIDA Study Group.
AIDS. 2004 Sep 3;18(13):1795-804
abstract
9 Cardio- and Cerebrovascular Events in HIV-Infected Persons. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller N; Writing Committee of the D:A:D: Study Group.
AIDS. 2004 Sep 3;18(13):1811-7
abstract
10 Changes in hospital admissions across Europe:1994-2003. Results from the EuroSIDA study. Mocroft A, d’Arminio Monforte A, Kirk O, Johnson M, Friis-Moller N,
Banhegyi D, Blaxhult A, Mulcahy F, Gatell J, Lundgren J for the EuroSIDA study group.
HIV Med. 2004 Nov;5(6):437-47
abstract
11 Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD; EuroSIDA Study Group.
J Infect Dis. 2004 Dec 1;190(11):1947-56 abstract
12 Causes of death in HIV infection:the key determinant to define the clinical response to anti-HIV therapy. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J; for the EuroSIDA study group.
AIDS. 2004 Nov 19;18(17):2333-2337 abstract
13 Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. Collaboration of HIV Cohorts, writting committee: Phillips AN, Ledergerber B, Lundgren JD, Hogg B, d'Arminio Monforte A, Castelli f, Walker S, Staszewski S, Thiébaut R, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D.
J Infect Dis. 2004;190:675-87 abstract
14 Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. May M, Royston P, Egger M, Justice AC, Sterne JAC and the ART Cohort Collaboration.
Statistics in Medicine 2004 23: 2375-98
2003
1 Modelling the three year risk of myocardial infarction among participants in the D:A:D study. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD; DAD Study Group.
HIV Med. 2003 Jan;4(1):1-10.
abstract
2 Changes in viral load in people with virological failure who remain on the Same HAART regimen. Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgren JD.
Antivir Ther. 2003 Apr;8(2):127-36
abstract
3 Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA et al.
AIDS. 2003 May 23;17(8):1179-93. abstract
4 Decline in the AIDS and death rates in the EuroSIDA study: an observational study. A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, A d’Arminio Monforte, B Knysz, M Dietrich, A N Phillips, J D Lundgren, for the EuroSIDA study group
Lancet. 2003 Jul 5;362(9377):22-9 abstract
5 Virological rebound after suppression on highly active antiretroviral therapy. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD; EuroSIDA study group.
AIDS. 2003 Aug 15;17(12):1741-51. abstract
6 Antiretroviral Therapy Cohort Collaboration.Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration.
Lancet. 2003 Aug 30;362(9385):679-86 abstract
7 Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A; The EuroSIDA Study Group.
HIV Med. 2003 Jul;4(3):255-262. abstract
8 Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.
Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.
N Engl J Med. 2003 Nov 20;349(21):1993-2003. abstract
9 Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, Colebunders R, Chiesi A, Lungren JD, Phillips AN a on behalf of the EuroSIDA group
J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):452-61 abstract
2002
1 A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio Monforte A, Hermans P, Goebel F-D, Blaxhult A, Kirk O, Phillips AN; The EuroSIDA Study Group.
J Infect Dis. 2002 Jan 15;185(2):178-87 abstract
2 Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: Results from the EuroSIDA study. Mocroft A, Phillips AN, Friis-Moller N, Colebunders R, Johnson AM, Hirschel B, Saint-Marc T, Staub T, Clotet B, Lundgren JD; EuroSIDA study group.
Antivir Ther. 2002 Mar;7(1):21-30 abstract
3 Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency VirusInfected Patients with Very Low CD4 Cell Counts. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormassen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD for the EuroSIDA Study group.
J Infect Dis. 2002 Jul 15;186(2):189-97. abstract
4 Changes in the cause of death among HIV positive subjects across Europe: Results from the EuroSIDA study. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, d’Arminio Monforte A, Fox Z, Lundgren JD for the EuroSIDA study group.
AIDS. 2002 Aug 16;16(12):1663-1671 abstract
5 Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H.
Ann Intern Med. 2002 Aug 20;137(4):239-50 abstract
6 Analysis of virological efficacy in trials of antiretroviral regimens: Drawbacks of not including viral load measurements after premature discontinuation of therapy. Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, Eron JJ Jr, Phillips AN, Lundgren JD.
Antivir Ther. 2002 Dec;7(4):271-81. abstract
7 Regional and temporal changes in AIDS in Europe before HAART. Blaxhult A, Fox Z, Colebunders R, Francioli P, Ben-Ishai Z, Fätkenheuer G, Parkin JM, Vanhems P, Phillips AN, Kirk O; EuroSIDA Study Group.
Epidemiol Infect. 2002 Dec;129(3):565-76. abstract
8 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration.
Lancet. 2002 Jul 13;360(9327):119-29. abstract
2001
1 Discontinuation of Secondary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, d'Arminio Monforte A, Schneider MME, and Lundgren JD, for eight European Study Groups.
N Engl J Med. 2001 Jan 18;344(3):168-74 abstract
2 The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study. Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM , Weber R, Roge B, Lazzarin A, Lundgren JD on behalf of the EuroSIDA study group.
AIDS. 2001 Jan 26;15(2):201-9 abstract
3 Influence of Age on CD4 Cell Recovery in Human Immunodeficiency Virus-Infected Patients Receiving Highly Active Antiretroviral Therapy: Evidence from the EuroSIDA Study.Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren JD; EuroSIDA Study Group.
J Infect Dis. 2001 Apr 15;183(8):1290-4 abstract
4 Clinical outcome among HIV-infected patients starting Saquinavir hard gel compared to Ritonavir or Indinavir: Results from the EuroSIDA Study. Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, Miller V, Viard JP, Phillips AN, Lundgren JD; EuroSIDA Study Group.
AIDS. 2001 May 25;15(8):999-1008 abstract
5 Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD.
AIDS. 2001 Dec 7;15(18):2385-2395 abstract
6 Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhoj P, Barton SE; EuroSIDA Study Group
Blood. 2001 Dec 1;98(12):3406-12 abstract
7 HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B.
JAMA. 2001 Nov 28;286(20):2560-2567 abstract
2000
1 Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe. Results From the EuroSIDA Study Paredes R, Morcroft A, Kirk O, Lazzarin A, Barton SE, Van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B for the EuroSIDA study group.
Arch Intern Med. 2000 Apr 24;160(8):1123-32. abstract
2 Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected Patients after the Introduction of Highly Active Antiretroviral Therapy. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, Barton SE, Sudre P, Phillips AN, Lundgren JD for the EuroSIDA study group.
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):865-72 abstract
3 AIDS across Europe, 1994-98: the EuroSIDA study Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD for the EuroSIDA study group.
Lancet. 2000 Jul 22;356(9226):291-6 abstract
4 Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. Mocroft A, Miller V, Chiesi A, Blaxhult A, Katlama C, Clotet B, Barton S, Lundgren JD on behalf of the EuroSIDA study group
Antivir Ther. 2000 Jun;5(2):107-12 abstract
1999
1 Relations among CD4 lymphocyte count nadir, antiretroviral therapy and HIV-1 disease progression: results from the EuroSIDA study. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD, for the EuroSIDA study group.
Ann Intern Med. 1999 Apr 6;130(7):570-7 abstract
2 Anaemia is an independent predictive marker for the clinical prognosis in HIV-infected patients from across Europe. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, d'Arminio Monforte A, Ledergerber B, Lundgren JD, for the EuroSIDA study group.
AIDS. 1999 May 28;13(8):943-50 abstract
3 Discontinuation of Pneumocystis carinii pneumonia prophylaxis after the initiation of highly activ antiretroviral therapy in HIV infection. Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzáles-Lahoz J, d'Arminio Montforte A, Proenca R, Phillips AN, Lundgren JD, Reiss P for the EuroSIDA Study Group
Lancet. 1999 Apr 17;353(9161):1293-8 abstract
4 Regional survival differences across Europe in HIV positive People: The EuroSIDA Study.Chiesi A, Mocroft A, Dally LG, Miller V, Katlama C, Ledergerber B, Pedersen C, Phillips AN, Vella S, Lundgren JD, for the EuroSIDA study group.
AIDS. 1999 Nov 12;13(16):2281-8 abstract
5 Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials Phillips AN, Grabar S, Tassie J-M, Costagliola D, Lundgren JD, Egger M
AIDS. 1999 Oct 22;13(15):2075-82 abstract
6 Does European or non-European origin influence health care and prognosis for HIV-patients in Europe? Blaxhult A, Mocroft A, Phillips A, van Lunzen J, Bentwich Z, Stergiou G, Colebunders R, Benfield TL, Mulcahy F, Lundgren JD.
HIV Med. 1999 Oct;1(1):2-9 abstract
1998
1 A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD
J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78 abstract
2 Survival in 2367 Zidovudine-Treated Patients According to Use of Other Nucleoside Analogue Drugs Phillips AN, Katlama C, Barton S, Vella S, Blaxhult A, Clotet B, Goebel F-D, Hirschel B, Pedersen C, Lundgren JD, for the EuroSIDA Study Group.
J Acquir Immune Defic Syndr. 1998;17:239-44. abstract
3 Changes in Use of Antiretroviral Therapy in Regions of Europe over time. Kirk O, Mocroft A, Katzenstein T, Lazzarin A, Antunes F, Francioli P, Brettle RP, Parkin JM, Gonzales-Lahoz J, Lundgren JD, for the EuroSIDA study group.
AIDS. 1998,12:2031-9 abstract
4 Changing Patterns of Mortality across Europe in Patients infected with HIV-1 Mocroft A, Vella S, Benfield T, Chiesi A, Miller V, Kosmidis J, d'Arminio Monforte A, Yust I, Bruun J, Phillips AN, Lundgren JD, for the EuroSIDA study group.
Lancet. 1998 Nov 28;352(9142):1725-30 abstract
1997
1 Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, Reiss P, Gatell J, Clumeck N, Dietrich M, Benfield TL, Nielsen JO, Pedersen C and the EuroSIDA study group.
J Acquir Immune Defic Syndr. 1997;16:153-60 abstract